I discuss issues pertaining to the practice of neuropathology -- including nervous system tumors, neuroanatomy, neurodegenerative disease, muscle and nerve disorders, ophthalmologic pathology, neuro trivia, neuropathology gossip, job listings and anything else that might be of interest to a blue-collar neuropathologist.
Tuesday, May 26, 2015
The Tumor Biomarker Series: EGFR
Epidermal growth factor receptor (EGFR) is the most frequently amplified oncogene in astrocytic tumors (>40% or GBMs and 5-10% of anaplastic astrocytomas). EGFR is far more often amplified in de novo GBMs as compared to secondary GBMs. About one-half of those GBMs with EGFR amplification also have specific EGFR mutations (the vIII mutant), which produce a truncated receptor with constitutive activity. Both EGFR amplification and EGFRvIII mutant are mutually exclusive with IDH mutations. So, what is the utility of EGFR testing? First, astrocytomas with EGFR amplification tend to be of higher grade. So if, for example, the diagnostician is vacillating between a WHO grade II and a WHO grade III tumor, positive EGFR amplification status would favor the latter. Secondly, EGFR amplification can also help distinguish between a small cell GBM (which would potentially harbor the amplification) from anaplastic oligodendrogliomas (which do not exhibit the amplification).
Wednesday, May 20, 2015
"Bad Ass" CrossFitter and Neuropathologist Greg Fuller set to compete in kettlebell competition for brain cancer research
Monday, May 11, 2015
The Tumor Biomarker Series: Ki-67
An immunohistochemical marker of cellular proliferation, the nuclear antigen Ki-67 is positive in cells that are actively engaged in cell cycle (i.e., not in G0). Results are expressed as a percent index of positively staining cells. Several studies have shows a correlation between Ki-67 indices in various astrocytomas, oligodendrogliomas, and mixed gliomas. Among grade II and grade III diffuse gliomas, the Ki-67 index provides prognostic value. However, investigations have consistently shown that Ki-67 proliferation indices have no prognostic value on patient outcomes for GBM. So, if you have an unmistakable GBM under your microscope, you are not practicing evidence-based parsimonious medicine by ordering Ki-67 immunohistochemistry on that tumor. On the other hand, if you are debating between diagnosing a grade III or a grade IV astrocytoma, Ki-67 can be helpful in swaying your decision. The Ki-67 index is not used in the WHO grading system because of the high degree of technical variability between laboratories, making standardization difficult.
Friday, May 8, 2015
The Tumor Biomarker Series: ATRX
Alpha Thalassemia/Mental Retardation Syndrome X-linked (ATRX) is a gene that encodes a protein involved in chromatin remodeling. ATRX mutations are a marker of astrocytic lineage among the IDH-mutant gliomas and are mutually exclusive with 1p/19q codeletion. Present in 57% of secondary GBMs, ATRX mutations are uncommon in primary glioblastomas. Nearly all diffuse gliomas with IDH and ATRX mutations also have TP53 mutation and are associated with the Alternative Lengthening of Telomeres (ALT) phenotype. Immunohistochemistry for ATRX demonstrates loss of protein expression in neoplastic cells harboring the inactivating mutations, while expression is retained within non-neoplastic internal controls (such as endothelial cells).
Tuesday, May 5, 2015
The Tumor Biomarker Series: PTEN and LOH of chromosome 10
Loss of heterozygosity (LOH) of chromosome 10 occurs in most GBMs and less frequently in grade II and III diffuse astrocytomas. The phosphatase and tensin (PTEN) gene at 10q23.3 has been most strongly implicated as a glioma-related tumor suppressor on chromosome 10q, with PTEN mutations identified in about 25% of GBMs and less frequently in grade III astrocytomas. Losses of chromosome 10 and mutations in PTEN are considered to be specific for astrocytic differentiation and are rare in oligodendrogliomas. They are also markers of high-grade progression and aggressive clinical behavior in astrocytomas.
Subscribe to: Posts (Atom)
Dr. Diamandis develops network to help pathologists interface with AI computational scientists
A neuropathology colleague in Toronto (Dr. Phedias Diamandis) is developing some amazing AI-based tools for pathology and academia. He hel...
Remarkable en bloc dissection of human central and peripheral nervous system accomplished at University of ColoradoShannon Curran, MS with her dissection Shannon Curran, a graduate student in the Modern Human Anatomy Program at the University of Co...
The meticulously extracted nervous system of a 19th-century woman on display at Hahnemann Medical CollegeLast summer I put up a post about a remarkable whole nervous system dissection that was carried out at the University of Colorado School of ...